APA (7th ed.) Citation

MA, H., W, K., S, D., N, H., K, H., A, v. T., . . . M, R. (2022). Results of a Prospective Non-Interventional Post-Authorization Safety Study of Idelalisib in Germany. Clinical lymphoma, myeloma & leukemia, 22(8), e777. https://doi.org/10.1016/j.clml.2022.04.007

Chicago Style (17th ed.) Citation

MA, Hoechstetter, Knauf W, Dambacher S, Hucke N, Höhne K, van Troostenburg A, Ramroth H, Abenhardt W, and Rummel M. "Results of a Prospective Non-Interventional Post-Authorization Safety Study of Idelalisib in Germany." Clinical Lymphoma, Myeloma & Leukemia 22, no. 8 (2022): e777. https://doi.org/10.1016/j.clml.2022.04.007.

MLA (9th ed.) Citation

MA, Hoechstetter, et al. "Results of a Prospective Non-Interventional Post-Authorization Safety Study of Idelalisib in Germany." Clinical Lymphoma, Myeloma & Leukemia, vol. 22, no. 8, 2022, p. e777, https://doi.org/10.1016/j.clml.2022.04.007.